USD 2.59
↓ -0.07 (-2.63%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| SANA | -2.6 | -18.0 | -37.4 | -48.1 | -72.1 | -38.9 | -87.9 | -92.6 | -92.6 | -92.6 |
| S&P 500 | -0.6 | -0.5 | 2.3 | 7.3 | 12.1 | 32.1 | 27.0 | 90.7 | 191.4 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
đŸ’¡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | SANA |
| name | Sana Biotechnology, Inc. |
| price | 2.59 |
| changes percentage | -2.63 |
| change | -0.07 |
| day low | 2.55 |
| day high | 2.75 |
| year high | 12 |
| year low | 2.55 |
| market cap | 576186940 |
| price avg 50 | 4.03 |
| price avg 200 | 6.52 |
| exchange | NASDAQ |
| volume | 1674498 |
| avg volume | 1395059 |
| open | 2.64 |
| previous close | 2.66 |
| eps | -1.40 |
| pe | -1.85 |
| earnings announcement | 2025-03-06T05:00:00.000+0000 |
| shares outstanding | 222466000 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001770121 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -30865000 | -27731000 | -11.30 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 219842000 | 201003000 | 9.37 |
| operating expenses | 294940000 | 272564000 | 8.21 |
| interest income | 9938000 | 3762000 | 164.17 |
| interest expense | 0 | -15625000 | 100.00 |
| ebitda | -252390000 | -256939000 | 1.77 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -326900000 | -272564000 | -19.94 |
| operating income ratio | 0 | 0 | NaN |
| net income | -283255000 | -266388000 | -6.33 |
| net income ratio | 0 | 0 | NaN |
| eps | -1.46 | -1.41 | -3.55 |
Gross Profit: Gross Profit decreased to -31 million in 2023 from -28 million in 2022 representing a change of -11.3%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 295 million in 2023 from 273 million in 2022 representing a change of 8.21%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -252 million in 2023 from -257 million in 2022 representing a change of 1.77%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to -1.46 in 2023 from -1.46 in 2022 representing a change of -3.55%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 220 million in 2023 from 201 million in 2022 representing a change of 9.37%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to -327 million in 2023 from -273 million in 2022 representing a change of -19.94%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -283 million in 2023 from -266 million in 2022 representing a change of -6.33%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001770121 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -3895000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 47709000 | 36299000 | 31.43 |
| operating expenses | 67258000 | 48846000 | 37.69 |
| interest income | 2579000 | 3202000 | -19.46 |
| interest expense | 0 | 0 | NaN |
| ebitda | -57704000 | -46396000 | -24.37 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -61761000 | -52741000 | -17.10 |
| operating income ratio | 0 | 0 | NaN |
| net income | -59924000 | -50291000 | -19.15 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.25 | -0.21 | -19.05 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from -4 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 48 million in 2024Q3 from 36 million in 2024Q2 representing a change of 31.43%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -58 million in 2024Q3 from -46 million in 2024Q2 representing a change of -24.37%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -62 million in 2024Q3 from -53 million in 2024Q2 representing a change of -17.1%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -60 million in 2024Q3 from -50 million in 2024Q2 representing a change of -19.15%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 67 million in 2024Q3 from 49 million in 2024Q2 representing a change of 37.69%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.25 in 2024Q3 from -0.25 in 2024Q2 representing a change of -19.05%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001770121 | |||
| total assets | 565299000 | 822720000 | -31.29 |
| total liabilities | 277793000 | 323405000 | -14.10 |
| total equity | 287506000 | 499315000 | -42.42 |
| cash and cash equivalents | 133517000 | 176765000 | -24.47 |
| short term investments | 71678000 | 247198000 | -71.00 |
| long term investments | 0 | 10051000 | -100.00 |
| total current assets | 213515000 | 444437000 | -51.96 |
| total non current assets | 351784000 | 378283000 | -7.01 |
| total current liabilities | 64486999 | 111504000 | -42.17 |
| total non current liabilities | 213306000 | 211901000 | 0.66 |
| common stock | 20000 | 19000 | 5.26 |
| retained earnings | -1338091000 | -1054836000 | -26.85 |
| total debt | 104096000 | 108253000 | -3.84 |
Total Assets: Total Assets decreased to 565 million in 2023 from 823 million in 2022 representing a change of -31.29%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 288 million in 2023 from 499 million in 2022 representing a change of -42.42%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 134 million in 2023 from 177 million in 2022 representing a change of -24.47%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 72 million in 2023 from 247 million in 2022 representing a change of -71.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 214 million in 2023 from 444 million in 2022 representing a change of -51.96%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,338 million in 2023 from -1,055 million in 2022 representing a change of -26.85%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 278 million in 2023 from 323 million in 2022 representing a change of -14.1%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 64 million in 2023 from 112 million in 2022 representing a change of -42.17%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 5.26%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 104 million in 2023 from 108 million in 2022 representing a change of -3.84%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001770121 | |||
| total assets | 559392000 | 618667000 | -9.58 |
| total liabilities | 266914000 | 279018000 | -4.34 |
| total equity | 292478000 | 339649000 | -13.89 |
| cash and cash equivalents | 126996000 | 138790000 | -8.50 |
| short term investments | 72011000 | 116685000 | -38.29 |
| long term investments | 0 | 0 | NaN |
| total current assets | 210149000 | 263452999 | -20.23 |
| total non current assets | 349243000 | 355214000 | -1.68 |
| total current liabilities | 47004000 | 50689000 | -7.27 |
| total non current liabilities | 219910000 | 228328999 | -3.69 |
| common stock | 22000 | 22000 | 0.00 |
| retained earnings | -1555781000 | -1495857000 | -4.01 |
| total debt | 96084000 | 98557000 | -2.51 |
Total Assets: Total Assets decreased to 559 million in 2024Q3 from 619 million in 2024Q2 representing a change of -9.58%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 292 million in 2024Q3 from 340 million in 2024Q2 representing a change of -13.89%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 127 million in 2024Q3 from 139 million in 2024Q2 representing a change of -8.5%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 72 million in 2024Q3 from 117 million in 2024Q2 representing a change of -38.29%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 210 million in 2024Q3 from 263 million in 2024Q2 representing a change of -20.23%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,556 million in 2024Q3 from -1,496 million in 2024Q2 representing a change of -4.01%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 267 million in 2024Q3 from 279 million in 2024Q2 representing a change of -4.34%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 47 million in 2024Q3 from 51 million in 2024Q2 representing a change of -7.27%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 96 million in 2024Q3 from 99 million in 2024Q2 representing a change of -2.51%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001770121 | |||
| net change in cash | -49924000 | -74575000 | 33.06 |
| operating cash flow | -253582000 | -290050000 | 12.57 |
| free cash flow | -273614000 | -310926000 | 12.00 |
| capital expenditure | -20032000 | -20876000 | 4.04 |
| depreciation and amortization | 24557000 | 15625000 | 57.16 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 35533000 | 38337000 | -7.31 |
| accounts payables | 1027000 | 1058000 | -2.93 |
| inventory | 0 | 0 | NaN |
| acquisitions net | -192044 | -231438 | 17.02 |
| investments in property plant and equipment | -20032000 | -20876000 | 4.04 |
| net cash used for investing activites | 172012000 | 210562000 | -18.31 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 31646000 | 4913000 | 544.13 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 31646000 | 4913000 | 544.13 |
| cash at end of period | 137349000 | 187273000 | -26.66 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 187273000 | 261848000 | -28.48 |
Net Change in Cash: Net Change in Cash increased to -50 million in 2023 from -75 million in 2022 representing a change of 33.06%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -254 million in 2023 from -290 million in 2022 representing a change of 12.57%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -274 million in 2023 from -311 million in 2022 representing a change of 12.0%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 36 million in 2023 from 38 million in 2022 representing a change of -7.31%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2023 from 1 million in 2022 representing a change of -2.93%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -20 million in 2023 from -21 million in 2022 representing a change of 4.04%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001770121 | |||
| operating cash flow | -51819000 | -58541000 | 11.48 |
| free cash flow | -55912000 | -71597000 | 21.91 |
| capital expenditure | -4093000 | -13056000 | 68.65 |
| depreciation and amortization | 4057000 | 3895000 | 4.16 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 10770000 | 11380000 | -5.36 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -507000 | 667000 | -176.01 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -4093000 | -13056000 | 68.65 |
| net cash used for investing activites | 41775000 | 5818000 | 618.03 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -29000 | -439000 | 93.39 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 2082000 | 10627000 | -80.41 |
| net change in cash | -7962000 | -42096000 | 81.09 |
| cash at end of period | 130828000 | 138790000 | -5.74 |
| cash at beginning of period | 138790000 | 180886000 | -23.27 |
Net Change in Cash: Net Change in Cash increased to -8 million in 2024Q3 from -42 million in 2024Q2 representing a change of 81.09%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -52 million in 2024Q3 from -59 million in 2024Q2 representing a change of 11.48%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -56 million in 2024Q3 from -72 million in 2024Q2 representing a change of 21.91%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 11 million in 2024Q3 from 11 million in 2024Q2 representing a change of -5.36%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of -176.01%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -4 million in 2024Q3 from -13 million in 2024Q2 representing a change of 68.65%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -1.46 | -1.41 | -2.94 |
| operating cash flow per share | -1.3 | -1.54 | 15.36 |
| free cash flow per share | -1.41 | -1.65 | 14.80 |
| cash per share | 1.05 | 2.25 | -53.14 |
| book value per share | 1.48 | 2.65 | -44.25 |
| tangible book value per share | 0.45 | 1.59 | -71.66 |
| shareholders equity per share | 1.48 | 2.65 | -44.25 |
| interest debt per share | 0 | 0.49 | -100.00 |
| market cap | 793727280 | 743958800 | 6.69 |
| enterprise value | 764306280 | 675446800 | 13.16 |
| pe ratio | -2.8 | -2.79 | -0.34 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -3.13 | -2.56 | -22.03 |
| pfcf ratio | -2.9 | -2.39 | -21.24 |
| pb ratio | 2.76 | 1.49 | 85.29 |
| ptb ratio | 2.76 | 1.49 | 85.29 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -3.03 | -2.63 | -15.20 |
| ev to operating cash flow | -3.01 | -2.33 | -29.43 |
| ev to free cash flow | -2.79 | -2.17 | -28.59 |
| earnings yield | -0.36 | -0.36 | 0.34 |
| free cash flow yield | -0.34 | -0.42 | 17.52 |
| debt to equity | 0 | 0.22 | -100.00 |
| debt to assets | 0 | 0.13 | -100.00 |
| net debt to ebitda | 0.12 | 0.27 | -56.28 |
| current ratio | 3.31 | 3.99 | -16.93 |
| interest coverage | 0 | 17.44 | -100.00 |
| income quality | 0.9 | 1.08 | -16.83 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.35 | 0.24 | 45.54 |
| capex to operating cash flow | -0.08 | -0.07 | -9.76 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.82 | 1.34 | -38.94 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 6.96 | 9.19 | -24.25 |
| roic | -1.14 | -0.44 | -156.39 |
| return on tangible assets | -0.78 | -0.43 | -81.23 |
| graham net net | -0.37 | 0.53 | -169.90 |
| working capital | 149028001 | 332933000 | -55.24 |
| tangible asset value | 87684000 | 299493000 | -70.72 |
| net current asset value | -64278000 | 121032000 | -153.11 |
| invested capital | 494442001 | 692158000 | -28.57 |
| average receivables | 0 | 0 | NaN |
| average payables | 3482499.5 | 2538000 | 37.21 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 48.58 | 37.6 | 29.19 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 7.51 | 9.71 | -22.59 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.99 | -0.53 | -84.67 |
| capex per share | 0.1 | 0.11 | -7.10 |
ROE: Return on Equity (ROE) decreased to -0.99 on 2023-12-31 from -0.53 on 2022-12-31, representing a change of -84.67%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.80 on 2023-12-31 from -2.79 on 2022-12-31, representing a change of -0.34%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.31 on 2023-12-31 from 3.99 on 2022-12-31, representing a change of -16.93%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from 0.22 on 2022-12-31, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| SANA | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.25 | -0.21 | -18.66 |
| operating cash flow per share | -0.22 | -0.25 | 11.85 |
| free cash flow per share | -0.24 | -0.31 | 22.23 |
| cash per share | 0.85 | 1.09 | -22.42 |
| book value per share | 1.24 | 1.45 | -14.24 |
| tangible book value per share | 0.39 | 0.6 | -34.01 |
| shareholders equity per share | 1.24 | 1.45 | -14.24 |
| interest debt per share | 0 | 0.04 | -100.00 |
| market cap | 979313920 | 1282386800 | -23.63 |
| enterprise value | 948401920 | 1242153800 | -23.65 |
| pe ratio | -4.09 | -6.37 | 35.91 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -18.9 | -21.91 | 13.73 |
| pfcf ratio | -17.52 | -17.91 | 2.21 |
| pb ratio | 3.35 | 3.78 | -11.32 |
| ptb ratio | 3.35 | 3.78 | -11.32 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -16.44 | -26.77 | 38.61 |
| ev to operating cash flow | -18.3 | -21.22 | 13.74 |
| ev to free cash flow | -16.96 | -17.35 | 2.23 |
| earnings yield | -0.06 | -0.04 | -56.03 |
| free cash flow yield | -0.06 | -0.06 | -2.26 |
| debt to equity | 0 | 0.03 | -100.00 |
| debt to assets | 0 | 0.02 | -100.00 |
| net debt to ebitda | 0.54 | 0.87 | -38.22 |
| current ratio | 4.47 | 5.2 | -13.98 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.86 | 1.16 | -25.71 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.36 | 0.32 | 10.60 |
| capex to operating cash flow | -0.08 | -0.22 | 64.58 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 1.01 | 3.35 | -69.90 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 2.67 | 2.64 | 0.88 |
| roic | -0.21 | -0.15 | -39.99 |
| return on tangible assets | -0.17 | -0.12 | -38.80 |
| graham net net | -0.29 | -0.1 | -187.25 |
| working capital | 163145000 | 212763999 | -23.32 |
| tangible asset value | 92656000 | 139827000 | -33.74 |
| net current asset value | -56765000 | -15565001 | -264.70 |
| invested capital | 506833000 | 561648999 | -9.76 |
| average receivables | 0 | 0 | NaN |
| average payables | 3404000 | 4956000 | -31.32 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 88.2 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 1.02 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.2 | -0.15 | -38.37 |
| capex per share | 0.02 | 0.06 | -68.78 |
ROE: Return on Equity (ROE) decreased to -0.20 on 2024-09-30 Q3 from -0.15 on 2024-06-30 Q2, representing a change of -38.37%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 4.47 on 2024-09-30 Q3 from 5.20 on 2024-06-30 Q2, representing a change of -13.98%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -4.09 on 2024-09-30 Q3 from -6.37 on 2024-06-30 Q2, representing a change of 35.91%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-09-30 Q3 from 0.03 on 2024-06-30 Q2, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 0.15 which is lower than current price 2.59, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-11-14 17:00:00
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
Sentiment: Positive
Publish Date: 2024-11-14 16:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Negative
Publish Date: 2024-11-14 07:30:00
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
Sentiment: Positive
Publish Date: 2024-11-13 10:55:18
Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Sentiment: Negative
Publish Date: 2024-11-12 15:45:00
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
Sentiment: Positive
Publish Date: 2024-11-12 14:30:00
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Negative
Publish Date: 2024-11-12 07:30:00
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
Sentiment: Positive
Publish Date: 2024-11-11 10:35:17
Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sentiment: Negative
Publish Date: 2024-11-11 07:25:00
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
Sentiment: Neutral
Publish Date: 2024-11-08 09:00:00
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology
Sentiment: Negative
Publish Date: 2024-11-07 15:30:00
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
Sentiment: Positive
Publish Date: 2024-11-07 11:00:00
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-04 16:30:00
Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells
Sentiment: Positive
Publish Date: 2024-09-30 16:05:00
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
Sentiment: Positive
Publish Date: 2024-08-29 16:05:00
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.
Sentiment: Positive
Publish Date: 2024-08-26 16:05:00
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
đŸ’¡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
